The Medical Weight Loss and GLP-1 Treatment Program at Taylor Bariatric Institute does not use compounded GLP-1 or GIP/GLP-1 medications under any circumstance because of well-documented concerns regarding safety, potency, consistency, legality, and patient risk
MolProbity: more and better reference data for improved all-atom structure validation
510% weight loss is considered clinically meaningful with pharmacotherapy
Survodutide (from Boehringer Ingelheim) is another dual agonist targeting GLP-1 and glucagon, but without the GIP component
While companies like Novo Nordisk have taken steps to make the medications more available, many consumers still struggle to access them
After years of struggling to find the perfect supplements, Kourtney, alongside Lemme's dedicated medical team, invested years into formulating products with clinically-studied ingredients and premium botanicals that optimize your well-being